STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data

Zhenxin Wang; Guoqing Zhang; Zhongcheng Li; Jin Li; Hongbo Ma; Ailian Hei; Shunchang Jiao; Yi Hu; Shengjie Sun; Liangliang Wu; Ji Zhou; Yu Wang; Ellen He; Sven Skog

doi:10.2144/fsoa-2020-0130

STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data

Future Sci OA. 2020 Nov 23;7(3):FSO661. doi: 10.2144/fsoa-2020-0130.

Authors

Zhenxin Wang¹, Guoqing Zhang², Zhongcheng Li³, Jin Li⁴, Hongbo Ma⁴, Ailian Hei⁴, Shunchang Jiao¹, Yi Hu¹, Shengjie Sun¹, Liangliang Wu¹, Ji Zhou⁴, Yu Wang⁵, Ellen He⁴, Sven Skog⁴

Affiliations

¹ Department of Oncology, Affiliated Hospital of Suzhou University, Shizi Street 188, Gusu District, Suzhou, China.
² Department of Oncology, Peking 301 Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing 100853, China.
³ Department of Thoracic Surgery, Affiliated Hospital of Suzhou University, Shizi Street 188, Gusu District, Suzhou, China.
⁴ Department of Medicine, Shenzhen SSTK Precision Medicine Institute, A301, Building 1, 1301-76 Guanguang Road, Longhua District, Shenzhen, China.
⁵ Health Management Center of PLA 910 Hospital, Quanzhou 362000, Fujian, China.

Abstract

Aim: A prospective investigation of serum thymidine kinase 1 concentration (STK1p) was performed to evaluate its prognostic value in patients with non-small-cell lung carcinoma (NSCLCs).

Patients & methods: The STK1p values of 127 patients were determined by an enhanced chemiluminescent dot blot assay. The patients were recruited from March 2011 to December 2017.

Results: Kaplan-Meier plot showed that patients with elevated STK1p values had worse overall survival (OS), especially patients of early/middle stages. Multi-variable COX regression showed that STK1p value and combined treatment surgery + chemotherapy were independent prognostic factors for favorable OS.

Conclusion: STK1p is helpful in predicting OS of early/middle stages (I-IIIA) NSCLCs patients following a nonrandomized individual adapted treatment, but is may be not recommended in advanced stages (IIIB + IV) of NSCLCs.

Keywords: lung cancer; non-small-cell lung cancer (NSCLC); radical resection (RR); serum thymidine kinase 1 protein (STK1p); survival; thymidine kinase 1 (TK1).